Cytokines and chronic fatigue syndrome

Annals of the New York Academy of Sciences

Volumn 933, Issue , 2001, Pages 185-200

  Patarca, Roberto ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA 2 MICROGLOBULIN; CD8 ANTIGEN; CYTOKINE; CYTOKINE RECEPTOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; LYMPHOTOXIN; NEOPTERIN; PROSTACYCLIN; PROSTAGLANDIN E2; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL MODEL; CHRONIC FATIGUE SYNDROME; CONFERENCE PAPER; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FATIGUE; HUMAN; IMMUNOTHERAPY; MOUSE; MULTIPLE CHEMICAL SENSITIVITY; NONHUMAN; PERSIAN GULF SYNDROME; SYMPTOMATOLOGY; SYNDROME DELINEATION; T LYMPHOCYTE ACTIVATION;

ANIMALIA;

EID: 0035029026     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2001.tb05824.x     Document Type: Conference Paper

References (120)

1. Alterations in central cathecolamines associated with immune responses in adult and aged mice
2. The immune response evokes changes in brain noradrenergic neurons
3. Sympathico-adrenal system activity in a primary immune response
4. The central nervous system and immunity
5. Immunological and neuroendocrine responses of rats to prolonged or repeated stress
6. Chronic variable stress facilitates tumoral growth: Reversal by imipramine administration
7. A prospective study of depression and immune dysregulation in multiple sclerosis
8. Corticotropin-releasing factor and interleukin-1 receptors in the brain-endocrine-immune axis: Role in stress response and infection
9. Stress-induced immune suppression: Role of the autonomic nervous system
10. Widespread activation and consequences of interleukin-1 in the brain
11. Depression and immunity: A meta-analytic review
12. Reduction of immune function in life stress and depression
13. Major depressive disorder, alcoholism, and reduced natural killer cell cytotoxicity
14. Major depressive disorder: Role of age, sex, severity, and hospitalization
15. Distal colon motility and clinical parameters in depression
16. Distal colon motility as a predictor of antidepressant response to fenfluramine, imipramine, and clomipramine
17. Effects of clonidine on blood pressure, noradrenaline, cortisol, growth hormone, and prolactin plasma levels in low and high intestinal tone depressed patients
18. Role of stress in the exacerbation of chronic illness: Effects of clonidine administration on blood pressure and plasma norepinephrine, cortisol, growth hormone, and prolactin concentrations
19. Central neuronal pathways involved in depressive syndrome: Experimental findings
20. Plasma neurotransmitters and cortisol in chronic illness: Role of stress
21. Immunological correlates of the chronic fatigue syndrome
22. The 2H4 (CD45R) antigen is selectively decreased in multiple sclerosis lesions
23. Markers of inflammation and immune activation in chronic fatigue and chronic fatigue syndrome
24. Dysregulated expression of soluble immune mediator receptors in a subset of patients with chronic fatigue syndrome: Categorization of patients by immune status
25. Interindividual immune status variation patterns in patients with chronic fatigue syndrome: Association with the tumor necrosis factor system and gender
26. Natural cytokine antagonists and endogenous antiendotoxin core antibodies in sepsis syndrome
27. Assessment of immune mediator expression levels in biological fluids and cells: A critical appraisal
28. Chronic fatigue syndrome: An immunological perspective
29. Susceptibility to immunologically mediated fatigue in C57BL/6 versus Balb/c mice
30. Gulf War syndrome: Is it due to a systemic shift in cytokine balance towards a Th2 profile?
31. Interferon-induced proteins are elevated in blood samples of patients with chemically or vitally induced chronic fatigue syndrome
32. Alteration of type 1/type 2 cytokine pattern following adoptive immunotherapy of patients with chronic fatigue syndrome (CFS) using autologous ex vivo expanded lymph node cells
33. Interleukin-1 and interleukin-1 antagonism
34. Interleukin-1: Biology, pathophysiology, and clinical prospects
35. Dysregulated expression of tumor necrosis factor in the chronic fatigue immune dysfunction syndrome: Interrelations with cellular sources and patterns of soluble immune mediator expression
36. Serum levels of lymphokines and soluble cellular receptors in primary EBV infection and in patients with chronic fatigue syndrome
37. Cell-mediated immunity in patients with chronic fatigue syndrome, healthy controls, and patients with major depression
38. Clinical improvement in chronic fatigue syndrome is not associated with lymphocyte subsets of function or activation
39. Chronic fatigue syndrome - A controlled cross-sectional study
40. Production of interleukin-1 by peripheral blood mononuclear cells in patients with chronic fatigue syndrome
41. Circulating lymphokine levels in the chronic fatigue syndrome
42. Nervous system - Immune system communication
43. Corticotropin-releasing factor-producing neurons in the RT activated by interleukin-1
44. Immunoregulatory feedback between interleukin-1 and glucocorticoid hormones
45. Interleukin-1 stimulates the secretion of hypothalamic corticotropin-releasing factor
46. Release of multiple hormones by a direct action of interleukin-1 on pituitary cells
47. 2 release to suppress pulsatile release of luteinizing hormone, but not follicle-stimulating hormone
48. Review of neuroendocrine disturbances in the chronic fatigue syndrome: Indications for a role of the growth hormone-IGF-1 axis in the pathogenesis
49. Recombinant tumor necrosis factor and interleukin 1 enhance slow-wave sleep
50. Chronic fatigue syndrome: A working cased definition
51. Nonrestorative sleep and symptoms after a febrile illness in patients with fibrosis and chronic fatigue syndrome
52. Secretion of S-100 from rat C6 glioma cells
53. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down's syndrome and Alzheimer's disease
54. Modulation of endothelial cell function by different molecular species of interleukin-1
55. Interleukin-1 decreases renal sodium reabsorption: Possible mechanisms of endotoxin-induced natriuresis
56. Interleukin-1 and tumor necrosis factor inhibit cardiac myocyte beta-adrenergic responsiveness
57. Interleukin-1 beta, interleukin-1 receptor antagonist, and soluble interleukin-1 receptor type II secretion in chronic fatigue syndrome
58. Lymphocyte subsets, apoptosis, and cytokines in patients with chronic fatigue syndrome
59. Cachectin (tumor necrosis factor): A macrophage hormone governing cellular metabolism and inflammatory response
60. A novel form of TNF-cachectin in a cell surface cytotoxic transmembrane protein: Ramifications for the complex physiology of TNF
61. Cytokine production by adherent and non-adherent mononuclear cells in chronic fatigue syndrome
62. In vitro evidence for a dual role of tumor necrosis factor in human immunodeficiency virus type 1 encephalopathy
63. Elevated levels of tumor necrosis factor alpha in postdialysis fatigue
64. Cryopreservation of peripheral blood mononuclear cells
65. Interleukin-1 and tumor necrosis factor: Effector cytokines in autoimmune diseases
66. Interleukin-2: A class of T cell growth factor
67. Recent advances in the understanding of the biochemistry and clinical pharmacology of interleukin-2
68. Selective in vitro growth of T lymphocytes from normal human bone marrows
69. Recombinant interleukin-2 directly augments the cytotoxicity of human monocytes
70. Expression of Tac antigen on activated normal human B cells
71. Interleukin-2 and the chronic fatigue syndrome
72. Immune function in chronic active Epstein-Barr virus infection
73. Chronic fatigue: A prospective clinical and virologic study
74. Soluble interleukin-2 receptor: Detection and potential role in organ transplantation
75. Serum interleukin-2 receptor: Clinical and biological implications
76. CD4 T lymphocytes from patients with chronic fatigue syndrome have decreased interferon-gamma production and increased sensitivity to dexamethasone
77. B-cell stimulatory factor-1/interleukin-4
78. Generation and analysis of interleukin-4 deficient mice
79. Serum neopterin and interleukin-6 levels in chronic fatigue syndrome
80. Altered cytokine release in peripheral blood mononuclear cell cultures from patients with the chronic fatigue syndrome
81. In vitro effect of echinacea and ginseng on natural killer and antibody-dependent cell cytotoxicity in healthy subjects and chronic fatigue syndrome or acquired immunodeficiency syndrome
82. The interleukins
83. Interleukin-6: An overview
84. Cytokine dysregulation in the post-Q-fever syndrome
85. Persisting illness and fatigue in adults with evidence of Epstein-Barr virus infection
86. Evidence for active Epstein-Barr virus infection in patients with persistent, unexplained illnesses: Elevated anti-early antigen antibodies
87. Epstein-Barr virus-specific immune defects in patients with persistent symptoms following infectious mononucleosis
88. Review of laboratory findings for patients with chronic fatigue syndrome
89. Low natural syndrome: Clinical and immunologic features
90. Interferon and myalgic encephalomyelitis
91. Myalgic encephalomyelitis and alpha-interferon
92. Elevated apoptotic cell population in patients with chronic fatigue syndrome: The pivotal role of protein kinase RNA
93. Fatigue: Definitions, mechanisms, and paradigms for study
94. Endocrine-mediated mechanisms of fatigue during treatment with interferon-alpha
95. Pattern of neurobehavioral deficits with interferon alpha therapy for leukemia
96. Immune system activation and fatigue during treadmill running: Role of interferon
97. Characterization of the gamma interferon-mediated induction of antigen-presenting ability in P388D cells
98. In vitro interactions of purified cloned human interferons on NK cells: Enhanced activation
99. Interferon inhibits the suppressor T cell response of delayed hypersensitivity
100. Immunologic abnormalities in chronic fatigue syndrome
101. Elevation of bioactive transforming growth factor-beta in serum from patients with chronic fatigue syndrome
102. Neopterin: An early marker of development of pre-AIDS conditions in HIV-seropositive individuals
103. Pteridines and neuroimmune function and pathology
104. Nitric oxide synthase and antimicrobial armature of human macrophages
105. Nitric oxide and AIDS dementia
106. Effect of neopterin and 7,8-dihydroneopterin on tumor necrosis factor-alpha induced programmed cell death
107. Relationships of cognitive difficulties to immune measures, depression, and illness burden in chronic fatigue syndrome
108. Physical symptoms of chronic fatigue syndrome are exacerbated by the stress of Hurricane Andrew
109. Decreased serum tryptophan in patients with HIV-1 infection correlates with increased serum neopterin and with neurologic/psychiatric symptoms
110. Decreased serum tryptophan in patients with cancer cachexia correlates with increased serum neopterin
111. Quinolinic acid in tumors, hemorrhage, and bacterial infections of the central nervous system in children
112. Biochemical studies on AIDS dementia complex - Possible contribution of quinolinic acid during brain damage
113. Increased neopterin levels in brains of patients with human immunodeficiency virus type 1 infection
114. Pteridines in plasma and in cells of peripheral blood tumor patients
115. Quantitative detection of brain aberrations in human immunodeficiency virus type 1-infected individuals by magnetic resonance imaging
116. Chronic illness characterized by fatigue, neurologic and immunologic disorders, and active human herpesvirus 6 type infection
117. A comprehensive immunological analysis in chronic fatigue syndrome
118. Psychological stress and susceptibility to the common cold
119. Stress-associated immune modulation: Relevance to viral infections and chronic fatigue syndrome
120. Stress-associated immune modulation: Implications for infectious diseases?